Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Intangibles (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Intangibles for 12 consecutive years, with $474000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles fell 23.55% year-over-year to $474000.0, compared with a TTM value of $474000.0 through Sep 2025, down 23.55%, and an annual FY2024 reading of $583000.0, down 20.03% over the prior year.
  • Intangibles was $474000.0 for Q3 2025 at CytomX Therapeutics, down from $510000.0 in the prior quarter.
  • Across five years, Intangibles topped out at $1.1 million in Q1 2021 and bottomed at $474000.0 in Q3 2025.
  • Average Intangibles over 5 years is $802052.6, with a median of $802000.0 recorded in 2023.
  • The sharpest move saw Intangibles fell 11.44% in 2021, then dropped 23.55% in 2025.
  • Year by year, Intangibles stood at $1.0 million in 2021, then decreased by 14.3% to $875000.0 in 2022, then fell by 16.69% to $729000.0 in 2023, then decreased by 20.03% to $583000.0 in 2024, then dropped by 18.7% to $474000.0 in 2025.
  • Business Quant data shows Intangibles for CTMX at $474000.0 in Q3 2025, $510000.0 in Q2 2025, and $547000.0 in Q1 2025.